GB BPR for suppliers and formulators: the post-Brexit biocides landscape

GB BPR is HSE's retained version of the EU Biocidal Products Regulation, in force in Great Britain since the end of the Brexit transition period and amended since to work as a standalone GB regime. HSE is the competent authority. It covers biocidal products themselves (disinfectants, preservatives, pest control products and similar) and, in a narrower way, treated articles that rely on a biocidal active substance without being biocidal products in their own right.

The regime has kept moving through 2026, with amendment regulations affecting approval expiry dates and fresh HSE decisions on individual active substances. Treat any specific date in this article as something to confirm on the day, not as a settled fact.

GB BPR works in two layers, and mixing them up is where a lot of confusion starts. The active substance itself has to be approved for the relevant product type before any product containing it can be authorised. Separately, the biocidal product built from that substance has to be authorised in its own right, through one of several routes:

• National authorisation. HSE authorises a specific product or product family for the GB market. Renewal applications are due well before expiry, so the renewal window has to be tracked against every authorised product, not just noticed when a certificate is close to lapsing.
• Simplified authorisation. Available where the active substance meets the lower-risk criteria set out in the regulation. A simplified authorisation cannot be renewed and expires on the date stated on the certificate, which makes the expiry date itself the thing you cannot afford to lose track of.
• Same biocidal product authorisation. For a product that is identical to one already authorised, or already under assessment, in GB.
• Mutual recognition. Recognises an authorisation already granted by another evaluating competent authority, on a timeline set by that process rather than a fresh GB assessment.

Which route applies, and what the renewal or expiry timetable looks like for your specific product, is something to confirm with HSE's current guidance rather than take from a summary.

Separate from product authorisation, the GB Article 95 list names the suppliers approved to supply a given active substance and product type combination into Great Britain. To place a biocidal product on the GB market, a formulator generally needs to be able to show a clear, auditable purchase trail back to a supplier on that list for the active substance involved. It is not enough that the active substance is approved in principle. The specific supplier has to be on the list too.

Why it catches formulators out:

• It sits above the product. The Article 95 list controls the active substance and its supplier, which is a layer above the product authorisation itself. A change at either layer can affect the other.
• It is a live list. Substances and suppliers are added and removed. A supplier your formulation has relied on for years can come off the list, and the obligation to check falls on you, not on a notification arriving unprompted.
• It reaches treated articles too. Removal from the list does not only block new biocidal product authorisations. It can also stop a treated article that relies on that active substance from being placed on the GB market.
• Resubmission has its own deadline. Staying on the list is not a one-off event. Suppliers of the active substance have to resubmit to stay listed, on a timeline that depends on whether HSE is the evaluating authority for that substance.

GB BPR's definition of a treated article is broad: any substance, mixture or article that has been treated with, or intentionally incorporates, one or more biocidal products. A single component can bring the whole finished product into scope. A preservative in the foam inside a piece of furniture is enough to make the finished item a treated article, even though nobody would describe the furniture itself as a biocidal product.

Two obligations follow from that. First, the active substance used to treat the article has to be approved for the relevant use, or included on the GB simplified active substance list, before the article is placed on the GB market. Second, labelling is required specifically where a claim is made that the article has biocidal properties. Confirm exactly where your own products sit against both tests with HSE's current guidance rather than assume the answer carries over from the EU position.

None of the individual obligations above is conceptually difficult. What makes GB BPR expensive in practice is that the pieces have to stay aligned at the same time, across every product: which active substances are in which formulations, which suppliers those substances come from, whether those suppliers are still on the Article 95 list, what authorisation route each product holds and when it is due for renewal, and which finished products count as treated articles under the broad definition above. A change in any one of those, a supplier delisted, a product type reclassified, an authorisation approaching its renewal window, has to be caught and traced through to every product it touches.

That is composition and sourcing data doing double duty, in the same way it does for a customer compliance questionnaire or a distributor's downstream obligations. A single maintained record of active substances, suppliers and authorisation status, checked automatically against the current Article 95 list, is what turns this from a recurring manual audit into a routine check. The competent person still decides what it means for a given product. The system's job is making sure nothing is missed in the meantime.

• HSE — GB Biocidal Products Regulation (GB BPR)
• HSE — The GB Article 95 List
• HSE — National authorisation
• HSE — Treated articles

This is practical guidance, not legal advice.